Baird Reiterates Outperform on Regeneron (REGN) Following Positive Phase III Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to Baird Reiterates Outperform on Regeneron (REGN) Following Positive Phase III Data
April 1, 2016 10:00 AM EDT
ADVISORY, April 01, 2016 (GLOBE NEWSWIRE) --
What:Â Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN), a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Robert Landry, Senior Vice President and Chief Financial Officer, will ring the Opening Bell.Â
Where:Â Nasdaq MarketSite 4 Times Square 43rd & Broadway Broadcast Studio
When:Â Monday, April 4, 2016 9:15 a.m. to 9:30 a.m. ET Â Â Â Â Â
Regeneron Media... More
April 1, 2016 1:00 AM EDT
TARRYTOWN, N.Y and PARIS, April 1, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that two placebo-controlled Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD) met their primary endpoints. In the studies, known as LIBERTY AD SOLO 1 and SOLO 2, treatment with dupilumab as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, quality of life, and mental health.
"These are the first Phase 3 studies of a systemic therapy to demonstrate a significant improvement in moderate-to-severe atopic dermatitis, a chronic,... More
